2B BlackBio CE marks fungal infection test
This article was originally published in Clinica
Spanish personalised medicine specialist 2B BlackBio has CE marked a fungal infection test, called the BlackLight Fungal ID Kit, for sale in Europe. The test uses microsequencing to identify Candida and Aspergillus, the fungal species responsible for around 95% of all invasive fungal diseases found in hospitals, which have a mortality rate of 30-40%. Accurate identification allows faster prescription of the most appropriate antifungal treatment, improving patient prognosis and survival, and minimising the risk of drug resistance, the Madrid-based firm says. The test takes less than four hours to carry out, which is faster than traditional methods such as culture in combination with serological or biochemical tests, which can take from several days to a month. The product is not currently approved in the US, and 2B BlackBio told Clinica that it intended to wait until it is well-established in the European market before trying to gain FDA approval.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.